Sign In
Buy NUVA
$39.75
+0 (+0%)
At Close: Nov 30, 2023
NuVasive (NUVA) Reports Q2 Loss, Misses Revenue Estimates
09:15pm, Tuesday, 04'th Aug 2020
NuVasive (NUVA) delivered earnings and revenue surprises of 18.37% and -0.31%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
NuVasive Announces Second Quarter 2020 Financial Results
08:03pm, Tuesday, 04'th Aug 2020
NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial
Global Spine Biologics Market: Growth, Trends & Forecasts (2020-2025) - ResearchAndMarkets.com
12:00am, Tuesday, 04'th Aug 2020
The
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
12:00am, Sunday, 02'nd Aug 2020
Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts.
COVID-19 news flow continued to pour in,...
Will NuVasive (NUVA) Beat Estimates Again in Its Next Earnings Report?
04:10pm, Wednesday, 29'th Jul 2020
NuVasive (NUVA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
NuVasive (NUVA) Expected to Beat Earnings Estimates: Should You Buy?
04:33pm, Tuesday, 28'th Jul 2020
NuVasive (NUVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Global Stem Cell Therapy Market will grow by USD 588.22 mn during 2020-2024
NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today launched its Time to
NuVasive Spikes 5% After-Hours On Sharp Procedure Rebound
05:37am, Tuesday, 21'st Jul 2020
Spine tech stock NuVasive (NUVA) has announced preliminary results for the second quarter 2020, sending shares 5% higher in Monday’s after-hours trading. Despite a significant revenue decline in th
NuVasive Announces Certain Preliminary Unaudited Second Quarter 2020 Results
08:05pm, Monday, 20'th Jul 2020
NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced certain pr
NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, and the American Spine Reg
Were Hedge Funds Right About Ditching NuVasive, Inc. (NUVA)?
11:05pm, Thursday, 16'th Jul 2020
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filin
Patrick F. Williams Appointed Chief Financial Officer of STAAR Surgical
12:00am, Monday, 06'th Jul 2020
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye
NuVasive, Inc. (NASDAQ:NUVA) Shares Sold by HighTower Advisors LLC
08:14am, Saturday, 04'th Jul 2020
HighTower Advisors LLC reduced its position in NuVasive, Inc. (NASDAQ:NUVA) by 3.0% in the 1st quarter, HoldingsChannel.com reports. The fund owned 16,047 shares of the medical device company’s stoc
The Global Interventional Spine Devices Market will grow by $ 2.31 bn during 2020-2024
